Product Description
Glycopyrronium (Qbrexza) topical wipes are labeled for the treatment of hyperhidrosis. Glycopyrronium wipes contain a topically-dosed anticholinergic. When applied to the axillae, they reduce sweating in patients nine years and older with hyperhidrosis (Sourced from: https://www.aafp.org/afp/2019/0915/p372.html)
Mechanisms of Action: M1 Antagonist,M2 Antagonist,M3 Antagonist,M4 Antagonist,M5 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Chronic Obstructive Pulmonary Disease | Hyperhidrosis
Known Adverse Events: Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Headache | Pain Unspecified | Erythema | Pruritus | Keratoconjunctivitis Sicca | Mydriasis | Constipation
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Africa, Spain, Sweden, Thailand, Turkey, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 27
Highest Development Phases
Phase 3: Asthma|Asthma, Allergic|Chronic Obstructive Pulmonary Disease|Hyperhidrosis|Other
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| D5989C00001 THARROS | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-03-07 |
|
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2027-11-30 |
74% |
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2027-11-30 |
74% |
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2027-11-30 |
74% |
| TRITON | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2026-01-01 |
|
| D5985C00002 | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2025-09-05 |
74% |
| D5985C00002 | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2025-09-05 |
74% |